Is BPC-157 legal? Status in the US, UK, EU, Australia and Canada

BPC-157 is not an approved medicine in the US, UK, EU, Australia or Canada, and FDA's 2026 review reported that a search found no approved BPC-157 product in any country. Regulators in the US, UK, Australia and Canada treat BPC-157 marketed for health uses as an unapproved medicine that cannot lawfully be sold to the public. Australia also makes it illegal to possess without authority and allows only narrow exceptions, such as a product compounded for a particular person. It is banned in sport at all times.^{1,5,7,20,11,12,13,14,15}

United States

FDA's 2026 review states that BPC-157 has no official quality standard (a USP monograph) and is not a component of any FDA-approved drug. FDA treats BPC-157 products promoted for health uses as unapproved new drugs: in a 2023 warning letter to an online seller offering injectable and nasal-spray BPC-157, it said such new drugs may not be sold across state lines without prior FDA approval and that no approved application was in effect for them.^1,5

The open question in the US is compounding, where a pharmacy prepares a drug for an individual patient. Under section 503A of US drug law, a pharmacy may compound only from an ingredient that has a USP monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list, which is set through federal regulations. FDA had placed BPC-157 in Category 2, its list of substances that may present significant safety risks, citing possible unwanted immune reactions (immunogenicity), impurities and limited safety information. As of its 22 April 2026 update, FDA's Category 2 page lists BPC-157 among substances previously in Category 2 whose nominations were withdrawn by the nominators.^2,3

Leaving Category 2 did not put BPC-157 on the bulks list. FDA took it to its Pharmacy Compounding Advisory Committee on 23 July 2026 and proposed that it not be added, because it is not well characterised chemically, its safety and immunogenicity risks are unclear, and there is not enough evidence that it works for ulcerative colitis. The committee voted 8 to 6, with one abstention, to recommend adding it anyway. Advisory committee recommendations are not binding, and FDA said it would not make a final determination until the committee's input and its own reviews were complete. We found no final FDA decision as of 29 September 2026.^1,2,4,18

Selling BPC-157 has led to prison time. In July 2026 a federal judge in Indiana sentenced the owner of an online peptide company that labelled its products "for research use" to 70 months in prison after he pleaded guilty to selling unapproved drugs; CBS News reported that BPC-157 was among the unapproved drugs he was charged with selling. Separately, the US military's Operation Supplement Safety programme states that BPC-157 "is not a dietary ingredient" and lists it on the Defense Department's prohibited dietary supplement ingredients list.^19,17

United Kingdom

We found no MHRA or GOV.UK statement specific to BPC-157. The general rule is that a product is a medicine if it is presented as treating or preventing disease, which UK law defines to include injury, or if it is used to restore, correct or modify a body function through a pharmacological, immunological or metabolic action. The Human Medicines Regulations 2012 say a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product, subject to exceptions set out elsewhere in the Regulations.^6,7

In April 2026 the MHRA began investigating UK clinics promoting peptides, after a Guardian investigation found a clinic website describing BPC-157 as "aiding tissue repair and recovery from injuries". The MHRA confirmed the site was making medicinal claims, which is not permitted, and a spokesperson said that if clinics make medicinal claims for peptide injections, "the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012".²⁰

European Union and Germany

The European Medicines Agency (EMA) says all medicines must be authorised before they can be marketed, either through a single EU-wide (centralised) procedure or by national regulators. BPC-157 does not appear in EMA's data on centrally authorised medicines (downloaded 29 September 2026), and FDA's 2026 review found no BPC-157 monograph in the European Pharmacopoeia and no approved product in any country. We found no statement on BPC-157 from Germany's medicines regulator (BfArM) or German customs, so rules and enforcement in individual EU countries are not verified here.^8,9,1

Australia

Australia is the only one of the five where we found BPC-157 named in legislation. Since 1 June 2024 it has been a Schedule 4 (prescription-only) substance in the national Poisons Standard, and it is listed in Appendix D among "poisons for which possession without authority is illegal". The scheduling delegate at the Therapeutic Goods Administration (TGA) made the change after 48 referrals for importation of BPC-157 since 1 July 2022, to align it with other performance- and image-enhancing substances. The June 2026 edition of the Poisons Standard still lists it this way.^10,11

The TGA names BPC-157 as an example of an unapproved peptide product, meaning one not included in the Australian Register of Therapeutic Goods and not evaluated for safety, quality or effectiveness. Its August 2026 enforcement release states that it is unlawful to import, advertise, manufacture and supply unapproved peptide products, with criminal penalties of up to 7 years' imprisonment, and its guidance says "research use only" disclaimers do not make supply lawful. That month the TGA and NSW Police seized more than A$120,000 of peptide and steroid products, including a BPC-157 and TB-500 combination, from two homes allegedly linked to a social media influencer.^12,13

The same guidance sets out narrow lawful routes. A product dispensed or compounded for a particular person, or compounded by a hospital pharmacist for the hospital's patients, is generally exempt from inclusion in the register, although the pharmacist or doctor must still meet the conditions for exemption from a manufacturing licence and their professional practice standards. A person may import an unapproved peptide product under the Personal Importation Scheme only if every condition of the scheme is met, including a prescription or medical authorisation where required, and the TGA says products that do not clearly state the active ingredient and strength will not be considered for release.¹²

Canada

Health Canada's public advisory of 9 April 2026 lists BPC-157 among examples of unauthorised injectable peptide drugs it has seized and tells Canadians not to buy or use them. It says peptides are generally regulated as prescription drugs in Canada, that unauthorised drug products are illegal and have not been assessed for safety, efficacy or quality, and that "For Research Use Only" labels do not make products legal. It is working with the Canada Border Services Agency to stop unauthorised shipments, and notes that authorised drugs carry an eight-digit Drug Identification Number (DIN) on the label.¹⁴

Sport

The World Anti-Doping Agency (WADA) names BPC-157 in class S0, non-approved substances, which are prohibited at all times, in and out of competition. S0 covers substances with no current approval by any government health regulator for human therapeutic use. The 2027 List, which takes effect on 1 January 2027, keeps BPC-157 in S0.^15,16

Summary

PeptoKing does not give legal advice. Laws and enforcement change, and rules can differ within a country: in Australia, for example, state and territory laws may add further controls. This page reflects official sources checked on 29 September 2026. For a legal answer about your own situation, ask the relevant regulator or a qualified lawyer.¹²